1239908-20-3 Usage
Description
Ixazomib citrate (USAN) is a glycine derivative that serves as a prodrug for ixazomib, which is an active proteasome inhibitor. It is obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of 2,2'-2-[(1R)-1-amino-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diydiacetic acid. Ixazomib citrate is used in combination therapy for the treatment of multiple myeloma, a type of blood cancer.
Uses
Used in Pharmaceutical Industry:
Ixazomib citrate (USAN) is used as an anticancer agent for the treatment of multiple myeloma. It functions by inhibiting the proteasome, a cellular protein that degrades unneeded or damaged proteins, thus disrupting the cancer cell's ability to survive and proliferate.
Used in Combination Therapy:
Ixazomib citrate (USAN) is used as a component in combination therapy for multiple myeloma. This approach combines the use of ixazomib with other anticancer drugs to enhance the overall treatment efficacy and potentially improve patient outcomes by targeting different aspects of the cancer cell's biology.
Check Digit Verification of cas no
The CAS Registry Mumber 1239908-20-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,9,9,0 and 8 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1239908-20:
(9*1)+(8*2)+(7*3)+(6*9)+(5*9)+(4*0)+(3*8)+(2*2)+(1*0)=173
173 % 10 = 3
So 1239908-20-3 is a valid CAS Registry Number.
1239908-20-3Relevant articles and documents
PROCESS FOR THE PREPARATION OF IXAZOMIB CITRATE
-
Page/Page column 4; 5, (2019/03/17)
The present disclosure provides a process for the preparation of ixazomib citrate. An efficient, industrially feasible process for the preparation of ixazomib citrate of Formula I, optionally which the process can occur in a single pot.
A PROCESS FOR THE PREPARATION OF IXAZOMIB CITRATE
-
, (2018/09/21)
The present invention relates to a process for the preparation of compound of formula (I), wherein, R1 and R2 are each independently hydroxy, alkoxy, aryloxy, or aralkoxy; or R1 and R2 together form a moiety derived from an alpha-hydroxy carboxylic acid compound or a beta-hydroxy carboxylic acid compound, wherein the atom attached to boron in each case is an oxygen atom; or R1 and R2 together form the boronate esters of boronic acid.
NOVEL CRYSTALLINE FORMS OF IXAZOMIB CITRATE AND ITS PROCESS FOR PREPARATION THEREOF
-
, (2018/10/19)
The present invention related to novel crystalline forms of Ixazomib citrate of formula-I and its process for preparation thereof. The chemical structure of said compound represented by the following formula-I. This invention also provides a process for the preparation of Ixazomib citrate of formula-I and also its solid dispersions.